Rekvina Labs Ltd
₹0.00▲ +0.00 (+0.00%)
REKVINALABORATORIESLTD·NSE·Healthcare
Market Cap
64.70 Cr
PE Ratio
—
Volume
—
Day High - Low
—
52W High-Low
58.24 - 6.75
₹0.00▲ +0.00 (+0.00%)
Market Cap64.70 Cr
PE Ratio—
Volume—
Day High - Low—
52W High-Low58.24 - 6.75
Rekvina Labs Ltd (REKVINALABORATORIESLTD): company summary
Rekvina Labs Ltd (REKVINALABORATORIESLTD) is a micro-cap Healthcare company valued at ₹65 crore operating in Pharmaceuticals on the NSE and BSE.
Rekvina Labs Ltd (REKVINALABORATORIESLTD) is a micro-cap Healthcare company valued at ₹65 crore operating in Pharmaceuticals on the NSE and BSE.
- Financial performance
- Return on equity stands at 20.7%, a strong return on shareholder capital.
- Valuation multiples
- A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 16.77 times book value.
Generated from DocStoX data. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
Not currently trading — we have seen no trades on NSE or BSE recently. It may be suspended, delisted, or renamed after a corporate action. Not a live price.
DocStoX Score
3.6/10
Poor
Fair Value
Sign in to see
ROE
20.74%
Strong
P/E
—
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
52W₹6.75
₹58.24
DocStoX take
Supported by growth (7.5), but held back by valuation (0.0). Growth looks strong at 7.5, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you. Scored on 4 of 5 measures.
DocStoX score
Low confidence3.6
/10
Poor
Quality
Modest
ROE 20.7%
Valuation
Expensive
P/B 16.8× vs 1.7× warranted by ROE
Growth
Strong
Revenue +45.8% 10Y CAGR
Risk
Elevated
D/E 0.00
Momentum
No data
No technical indicators
Scored on 4 of 5 measures — the rest have no data for this company.
At a glance
Market Cap
₹65 Cr
52W High / Low
₹58 / ₹7
Dividend Yield
0.00%
Promoter Holding
77.00%
EPS (TTM)
₹-0.12
Book Value
₹3.47
Key highlights
- Revenue compounding 46% a year
- Low leverage — D/E 0.00
- Capital works hard — ROCE 21%
- Loss-making in some of the last 5 years
- Valuation is weak (0.0/10)
4 Positives3 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Rekvina Labs Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Rekvina Labs Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Rekvina Labs Ltd with peers
Related tools & concepts
Value Rekvina Labs Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing